Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Quanterix Corporation

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jade Biosciences (JBIO), MoonLake Immunotherapeutics (MLTX) and Q...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	QTRX	$2.76	+6.56%	648.72K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	QTRX	$2.76	+6.6%	648.72K
3
4
5
6

QTRX

Get Quanterix Corporation Data in Excel

Get Quanterix Corporation Data in Excel